ESC 365 - Efficacy and safety of Shexiang Baoxin pill in patients with ischemia with non-obstructive coronary arteries (LESS): a phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial

ESC Professional Premium Access

Efficacy and safety of Shexiang Baoxin pill in patients with ischemia with non-obstructive coronary arteries (LESS): a phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial

Session: Acute and chronic coronary syndromes

Topic: Clinical

Speaker: Mrs N. Li (Shanghai, CN)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mrs Na Li

Shanghai Changzheng Hospital of Naval Medical University, Shanghai (China)

0 follower

6 more presentations in this session

Methylome of circulating cell free DNA as a novel biomarker tool: from acute coronary syndrome to broader risk stratification of cardiovascular disease

Speaker: Doctor A. Kratzer (Berlin, DE)

How to predict myocardial injury in patients with large ischaemic burden identified during stress echocardiography?

Speaker: Doctor K. Vakalis (Harefield, Uxbridge, GB)

Longitudinal and cross-sectional associations of NT-proBNP with kidney function and chronic kidney disease: results from KORA cohort studies

Speaker: Mr J. Lin (Neuherberg, DE)

Coronary sinus reducer device for the treatment of refractory angina: a single center experience

Speaker: Doctor M. Sobral Domingues (Lisbon, PT)

Symptomatic patients without coronary artery disease do not have excess cardiovascular risk compared to the general population

Speaker: Doctor K. Olesen (Aarhus, DK)

Access the full session

Acute and chronic coronary syndromes

Speakers: Mrs N. Li, Doctor A. Kratzer, Doctor K. Vakalis, Mr J. Lin, Doctor M. Sobral Domingues...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources